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tendon stem cell characteristics and prevents
spontaneous differentiation in vitro
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Abstract
Background: Previous studies have reported that adult mesenchymal stem cells (MSCs) tend to gradually lose
their stem cell characteristics in vitro when placed outside their niche environment. They subsequently
undergo spontaneous differentiation towards mesenchymal lineages after only a few passages. We observed a
similar phenomenon with adult tendon stem cells (TSCs) where expression of key tendon genes such as
Scleraxis (Scx), are being repressed with time in culture. We hypothesized that an environment able to restore
or maintain Scleraxis expression could be of therapeutic interest for in vitro use and tendon cell-based
therapies.
Methods: TSCs were isolated from human cadaveric Achilles tendon and expanded for 4 passages. A high
content imaging assay that monitored the induction of Scx protein nuclear localization was used to screen
~1000 known drugs.
Results: We identified retinoic acid receptor (RAR) agonists as potent inducers of nuclear Scx in the small molecule
screen. The upregulation correlated with improved maintenance of tendon stem cell properties through inhibition of
spontaneous differentiation rather than the anticipated induction of tenogenic differentiation. Our results suggest that
histone epigenetic modifications by RAR are driving this effect which is not likely only dependent on Scleraxis nuclear
binding but also mediated through other key genes involved in stem cell self-renewal and differentiation. Furthermore,
we demonstrate that the effect of RAR compounds on TSCs is reversible by revealing their multi-lineage differentiation
ability upon withdrawal of the compound.
Conclusion: Based on these findings, RAR agonists could provide a valid approach for maintaining TSC stemness
during expansion in vitro, thus improving their regenerative potential for cell-based therapy.
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Background
Tendon stem cells (TSCs) have been characterized in
adult tendons and show similar differentiation properties
to bone marrow mesenchymal stem cells (BM-MSCs)
with the exception of expressing tendon specific markers
[1, 2]. Previous studies on mesenchymal stem cells
(MSCs) have also shown in vitro aging and spontaneous
differentiation during expansion over several passages
[3–5]. Similar to MSCs removed from their niche, the
absence of tendon extracellular matrix (ECM) in culture
interferes with TSC self-renewal and differentiation behav-
ior. This could explain the appearance of bone, adipose,
and cartilage markers upon expansion in vitro. TSC ex-
pansion for in vitro use, or potentially cell therapy still re-
main to be optimized in order to preserve their stem cell
characteristics while preventing premature differentiation.
Scleraxis (Scx) is a basic helix–loop–helix transcription
factor highly specific to tendon and has been shown to be
both sufficient and necessary to promote the tendon cell
fate [6–8]. Although little is known about Scx function in
stem cells, TSCs isolated from adult tendons express high
levels of Scx but gradually lose this expression after being
* Correspondence: JElliott@gnf.org
†Equal contributors
Genomics Institute of the Novartis Research Foundation, 10675 John Jay
Hopkins Drive, San Diego, CA 92121, USA
© 2016 Webb et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Webb et al. Stem Cell Research & Therapy  (2016) 7:45 
DOI 10.1186/s13287-016-0306-3
cultured. Scx is expressed throughout development and
decreases significantly during adulthood. It is known that
mechanical stimulation can upregulate Scx expression
under physiological loading both in vitro and in vivo, sug-
gesting that it might be required for tendon homeostasis
[9, 10]. A recent study also showed that overexpression of
Scx in TSCs promoted better repair compared with
untransduced cells when transplanted in a patellar tendon
injury model [11]. Therefore, we performed a high-
content imaging screen on TSCs to discover small mole-
cules able to induce Scx nuclear protein levels in later
passage TSCs when they have low nuclear signal. We hy-
pothesized that a drug increasing Scx signaling would be
beneficial in vitro for cell therapy aimed at promoting ten-
don regeneration and may also provide a suitable ex vivo
culture environment for TSCs.
Methods
Ethical approval
Achilles and patellar tendons from a 55-year-old human
cadaver were obtained following informed consent from
the subject or the subject’s legally authorized representa-
tive by Asterand Bioscience (Asterand, Detroit, MI, USA)
according to the Department of Health and Human
Services regulations for the protection of human subjects
(45 CFR §46.116 and §46.117) and Good Clinical Practice
(ICH E6). United States Postmortem Sites, except studies
being performed by Veterans Affairs (VA) investigators at
VA facilities or off-site VA locations, are exempt from in-
stitutional review board review because deceased donors
are not considered “human subjects” under federal regula-
tions for live donors (CFR 45 part 46). In compliance with
the federal regulation stated for postmortem tissues, no
approval from an ethics committee was necessary for this
study. For rat TSC isolation, Achilles tendons from Spra-
gue Dawley rats 3–4 months old were used following ap-
proval by the Institutional Animal Care and Use
Committee (IACUC-Protocol P14-357) at the Genomics
institute of the Novartis Research Foundation. The experi-
mental animals received care in compliance with the
Guide for the Care and Use of Laboratory Animals.
Isolation and expansion of TSCs
Surrounding connective tissue was removed and the tissue
was washed in Hank’s Balanced Salt Solution (HBSS) and
then transferred to 5 % dispase, 3 mg/ml collagenase type
1 (Worthington, Lakewood, NJ, USA) with antibiotics/
antimycotics. The tissue was digested at 37 °C for 12 hours.
The solution was then passed through a 50 μm cell
strainer and the cells were centrifuged at 350 × g for 20 mi-
nutes. Pelleted cells were resuspended in growth media
and plated at a density of ~750 cells/cm2 in MSC ex-
pansion media (Lonza, Basel, Switzerland). Cells were cul-
tured for 7–10 days at 37 °C, 5 % CO2. After colony
formation, the cells were trypsinized and expanded. Cell
lines from both human and rat origin were able to be
maintained in culture for >30 passages.
mRNA extraction and quantitative reverse transcription-
PCR analysis
mRNA was extracted using the RNeasy Plus kit (Qia-
gen, Germantown, MD, USA) as per the manufacturer’s
protocol. cDNA was synthesized from the isolated
mRNA using qScript cDNA SuperMix (Quanta Biosci-
ences, Gaithersburg, MD, USA) as per the manufac-
turer’s protocol. cDNA and primers were transferred
using the Echo liquid handler system (Labcyte, Sunny-
vale, CA, USA). Quantitative PCR was performed using
SYBR Green (Roche, Indianapolis, IN, USA) in a 5 ul re-
action and analyzed with the Roche 480 Lightcycler.
Raw c(t) values were converted to 2ΔΔc(t) for comparison
between samples. The average of three different house-
keeping genes was used as calibrators for the experiment:
GADPH (metabolic), 36B4 (ribosomal), and beta-actin
(cytoskeleton). Three biological replicates were used and
standard deviation (SD) was calculated for each condition.
For primer sequences, see Additional file 1: Table S1.
Immunocytochemistry and high-content imaging
Cells were plated at different densities and grown for the
indicated amounts of time. Cells were then fixed with 4 %
paraformaldehyde, electron microscopy grade (Electron
Microscopy Sciences, Hatfield, PA, USA), for 20–30 mi-
nutes at room temperature. Permeabilization and blocking
was performed with 3 % bovine serum albumin (Sigma,
St-Louis, MO, USA) and 0.2 % Triton X-100 (Sigma) in
phosphate-buffered saline (PBS) for 1 hour at room
temperature. Primary antibodies were diluted in blocking
buffer and stained overnight at 4 °C. Primary antibodies
against the following proteins were used: anti-SCX
(Abgent, San Diego, CA, USA), anti-Oct4 (Reprocell Inc.,
Boston, MA, USA), and anti-aggrecan (Millipore, Billerica,
MA, USA). After three washes with PBS, cells were incu-
bated with Alexa-Fluor 488 (Life Technologies, Carlsbad,
CA, USA) conjugated antibody and Hoechst 33342 dye
(Life Technologies) for 1 hour at room temperature. After
three washes with PBS, cells were then imaged.
In addition, cells treated with CD1530 (Tocris Bioscience,
Bristol, UK), all-trans retinoic acid (Tocris Bioscience, Bris-
tol, UK), CD2665 (Tocris Bioscience), transforming growth
factor beta-2 (TGFβ2; R&D Systems, Minneapolis, MN,
USA), BIX-01294 (Sigma) and C646 (Sigma) were stained
using the same method. High-content imaging was per-
formed in an ImageXpress Ultra Confocal System (Molecu-
lar Devices, Sunnyvale, CA, USA) and staining for Scx,
aggrecan, and nuclei was analyzed using MetaXpress 5.0
software (Molecular Devices).
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Differentiation assays
Cells were plated in MSC media (Lonza) at 80 % conflu-
ence into six-well dishes and incubated for 8–12 hours to
allow cell attachment. After the cells were attached, the
media were changed to the respective differentiation cock-
tails ± 100 nM tazarotene (Sigma) for 14 days in vitro
(DIV). Commercially available differentiation cocktails
used were StemPro® Adipogenesis, Osteogenesis, and
Chondrogenesis Differentiation Kits (Life Technologies).
After 14 days, cells were fixed with 4 % paraformaldehyde
for 30 minutes and stained for lineage specific markers.
Akaline phosphatase activity in osteoblasts was revealed
using Fast Blue RR (Sigma). Adipocytes were stained for
lipid accumulation with LipidTOX-Green (Life Technolo-
gies). After fixation, cells were incubated with PBS con-
taining LipidTOX for 1 hour and then imaged.
Chondrocytes were examined for aggrecan accumulation
using the immunofluorescence protocol already described.
Western blots
Cells were plated at confluence grown in the presence or
absence of 100 nM tazarotene for 4 days. Cells were har-
vested by scraping and were pelleted before extraction of
total crude protein or nuclear and cytoplasmic protein
fractions (NE-PER Reagents, Thermo Scientific, Waltham,
MA, USA). Proteins were run on 4–12 % Bis-Tris Gels
and transferred as recommended for Polyvinylidene
difluoride membrane (Life Technologies). Protein blots
were blocked with 3 % ECL Prime blocking buffer for
1 hour. All subsequent antibody incubations were per-
formed in 3 % ECL Prime blocking buffer. Antibodies
used were anti-SCXA (Abgent, San Diego, CA, USA)
and anti-rabbit horseradish peroxidase (GE Healthcare,
Chicaco, IL, USA). The signal was developed using
SuperSignal West Pico substrate (Thermo Scientific, Wal-
tham, MA, USA) and visualized using the ChemiDoc MP
Imaging System (Bio-Rad, Hercules, CA, USA).
Statistical analysis
Dose–response curves and statistical analysis were done
using Graphpad Prism software (San Diego, CA, USA).
To determine statistical significance between treatments,
an unpaired, two-tailed Student’s t test was used. For all
graphs, data are presented as mean ± SD. p <0.05 was
considered significant.
Results
A small low molecular weight screen to identify Scx
modulators
TSCs were isolated from human Achilles cadaveric ten-
dons and plated at low density for colony formation
(Fig. 1a). As reported previously, colonies were observed
following 7–10 days in culture and displayed heterogen-
eity in size and density but produced a morphologically
homogeneous population of polygonal shaped cells upon
expansion. Scx immunofluorescence on early passage
cells revealed strong nuclear immunoreactivity while nu-
clear localization was gradually lost upon expansion
(Fig. 1b, c). The Scx antibody specificity was confirmed
using a construct overexpressing human SCX protein in
293 cells which are negative for SCX expression, and
their TSC identity was confirmed using Oct4 staining
(Additional file 2: Figure S1). The decrease in nuclear
localization upon culturing was used to design a low
molecular weight (LMW) screen (~1000 different known
drugs) to identify Scx inducers. Cells were expanded up
to passage 4, a time when the vast majority of cells have
low nuclear localized Scx protein, and plated in a 384-
well format for high-throughput screening. The following
day, the cells were stimulated with the small molecules.
Cells were then grown for an additional 3 days, and then
fixed and stained for Scx. Using high-content imaging,
each individual well was visualized and analyzed using an
algorithm that quantifies Scx nuclear translocation.
TGFβ2, already known to induce Scx expression in TSCs,
was used as a positive control in our screen (Fig. 1d, e).
RAR agonists induce strong SCX nuclear localization in
human TSCs
Tazarotene, a RARβ and RARγ agonist, was identified as
a strong hit in our LMW screen due to intense nuclear
staining observed in treated cells (Fig. 2a, b). Further re-
confirmation was carried out using two other molecules
that also act as RAR agonists (CD1530 and ATRA). Both
RAR agonists recapitulated the effect seen with tazaro-
tene and showed expected half-maximal effective con-
centration which induces a response (EC50) values for
such compounds (Fig. 2c–e). Interestingly, RAR antag-
onist CD2665 was able to reduce SCX to levels lower
than dimethyl sulfoxide (DMSO) controls, suggesting
that endogenous RAR activity might play a role in SCX
maintenance (Fig. 2e). Cellular analysis revealed no de-
crease in total cell number or obvious change in morph-
ology with any of the compounds (up to 10 μM),
confirming that the nuclear localization observed was
not caused by nonspecific cytotoxicity (i.e., rounding of
the cells) (Fig. 2f, h, i). When added in combination,
CD2665 was also able to induce a shift in the tazarotene
EC50 curve, confirming RAR as the target (Fig. 2g). Al-
though human cells treated with tazarotene exhibited an
increase in nuclear Scx protein, the total protein levels
remained unchanged, suggesting activation through nu-
clear translocation rather than general protein increase
(Fig. 2j). We also observed a similar phenotype with
TSCs isolated from human patellar tendon, suggesting
the effect is not unique for Achilles TSCs but is also
conserved in TSCs isolated from other tendons
(Additional file 3: Figure S2).
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Tazarotene can maintain TSC identity and block
differentiation into different mesenchymal lineages
Because of the limited availability of human cells at early
passage, the differentiation experiments and further
characterization were performed using rat TSCs isolated
using an identical protocol. The increase in the nuclear
Scx protein following stimulation with tazarotene was
confirmed in rat TSCs by western blot using a different
Scx commercial antibody that cross-reacts with rat scler-
axis protein (Additional file 4: Figure S3). Tazarotene,
which was the most potent RAR agonist tested in our
assay, was used at 100 nM for subsequent experiments
because this concentration gives close to 100 % efficacy
at inducing Scx nuclear localization (Fig. 2e).
Even though Scx is expressed in TSCs, its increase in
expression has also been associated with tenogenic dif-
ferentiation both in vitro and in vivo [6, 7, 12–14]. To
determine whether tazarotene could potentially induce
tenogenesis, a differentiation time-course assay was per-
formed in vitro. Following confluency, a time-dependent
increase in tendon gene expression (EphA4, Col1a1, and
Fmod) was observed, reaching a maximum at 7 days.
However, cells treated with tazarotene did not show a
greater increase in expression and instead displayed
mRNA levels at day 7 similar to those seen at day 1, sug-
gesting that tazarotene is perhaps maintaining the cells
in an undifferentiated state (Fig. 3a–c). TSCs have the
ability to differentiate into each of the major MSC line-
ages when stimulated in the appropriate conditions.
When treated with osteogenic, adipogenic, or chondro-
genic induction cocktails, the cells responded as pre-
dicted—shown by specific histological staining and
quantitative PCR for each lineage. Osteogenic induction
media caused an upregulation of the alkaline phosphat-
ase (Alp) messenger RNA as well as by fast blue staining
(Fig. 3d, g). Adipogenic induction media caused an up-
regulation of Foxo1 and lipid accumulation shown with
LipidTOX-Green staining, while chondrogenic media in-
creased expression of both aggrecan and collagen type 2
(Fig. 3e, f, h, i). Each of the lineages also took on the
characteristic morphology of their respective lineage.
Addition of tazarotene was able to suppress the induc-
tion of differentiation for all lineages, as seen by negative
staining and low mRNA levels for up to 7 days (Fig. 3a–i).
Inversely, treatment with tazarotene could maintain stem
cell markers (Oct4 and Ssea-1) for up to 7 days, confirm-
ing the inhibition of differentiation and maintenance of a
stem cell phenotype (Fig. 4a–d).
Fig. 1 A small LMW screen designed to identify Scx upregulators using high-content imaging a. Human TSCs lose nuclear Scx nuclear localization
with passages b, c. Hits were identified as strong Scx inducers by displaying higher levels compared with our positive control, TGFβ2 d, e. LMW
low molecular weight, Scx scleraxis, TGFβ2 transforming growth factor beta-2, TSC tendon stem cell
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Tazarotene prevents spontaneous differentiation during
expansion
It is known that MSCs from different origins change pro-
gressively in culture, with some cells undergoing spontan-
eous or premature differentiation during successive
passages [3–5]. Since TSCs are relatively similar to MSCs,
we hypothesized that the expansion of cells in the pres-
ence of tazarotene would prevent this process and pre-
serve their stem cell characteristics. To test this
hypothesis, TSCs were isolated from naïve rat Achilles
tendons and plated at clonal density for 7 days. Colonies
were then trypsinized and plated at subconfluency with or
without tazarotene. Every 3–4 days, the same of amount
of cells from either condition were replated and treated
for four consecutive passages. mRNA was harvested at the
first and fourth passages for gene expression analysis
(Fig. 5a). As hypothesized, cells grown in the absence of
tazarotene showed an increase in several markers associ-
ated with differentiation towards multiple mesenchymal
lineages. Gene expression level comparison from passage
1 with passage 4 revealed significant upregulation of teno-
genic (EphA4, Col1a1, Col3a1, Bgn), osteogenic (Runx2),
adipogenic (Foxo1), and chondrogenic (Col2a1) genes
(Fig. 5b, d). Inversely, stem cell marker expression (Oct4
and Ssea-1) was higher in tazarotene expanded cells
(Fig. 5c). The preservation of stem cell marker expression
could be observed over several passages (Additional file 5:
Figure S4). These findings suggest tazarotene could
maintain the TSC phenotype and prevent spontaneous
differentiation during cell expansion.
Fig. 2 RAR agonists induce SCX nuclear localization in human TSCs a–d. The effect was observed in a dose–response manner and EC50 curves
could be generated from a SCX nuclear localization algorithm looking at nuclear translocation and corresponding cell counts for different RAR
agonists (tazarotene, CD1530, retinoic acid) and an antagonist (CD2665) e, f. Co-treatment with the RARγ antagonist CD2665 (1 μM) was able to
induce a shift in the tazarotene EC50 curve g. Phase-contrast images showing different cell morphologies between control and tazarotene-treated
cells h, i. Western blot quantification of total SCX protein remaining unchanged following treatment with tazarotene j ATRA all-trans retinoic acid,
DMSO dimethyl sulfoxide, hr hours, Scx scleraxis, Taz tazarotene
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Inhibition of differentiation by tazarotene is reversible
upon withdrawal
Because tazarotene appeared to prevent differentiation
in subconfluent conditions, we aimed to determine
whether this blockade was reversible upon removal of
the compound. TSCs grown in the presence of tazaro-
tene for nine passages were further expanded with or
without the compound for an additional three passages
and induced to differentiate into different lineages
(Fig. 6a). Cells from both of these conditions were then
plated in the absence of compound and induced to dif-
ferentiate into osteocytes, adipocytes, or chondrocytes
for 14 DIV while using the untreated passage 12 cells as
a control. Control cells displayed alkaline phosphatase
reactivity in addition to LipidTOX-Green and aggrecan-
positive staining when stimulated with osteogenic, adi-
pogenic, and chondrogenic media respectively (Fig. 6b,
e, h). Similar to the control cells, withdrawal of the com-
pound for three consecutive passages was sufficient to
restore multiple lineage differentiation capabilities to the
cells (Fig. 6c, f, i). Cells expanded in the presence of
tazarotene until the same passage number (passage 12)
were not able to differentiate despite the absence of the
compound in the induction media, suggesting that add-
itional cell divisions following withdrawal might be re-
quired to fully restore their competence to differentiate
(Fig. 5d, g, j). We also confirmed that tazarotene treat-
ment does not have a major impact on cell proliferation
at efficacious doses. The population doubling time at
concentrations between 20 and 500 nM did not show
significant difference compared with untreated cells and
was also unchanged following withdrawal of the com-
pound (Additional file 6: Figure S5).
Histone methylation appears necessary for SCX nuclear
induction by tazarotene
To verify any possible epigenetic histone modifications
induced by RAR, we took advantage of the Scx nuclear
translocation assay and tested different histone methyl-
transferase and acetyltransferase inhibitors (BIX-01294
Fig. 3 RAR agonists can prevent tenogenic differentiation and other instructed mesenchymal lineages in rat ATSCs (passage 6) following long-term
differentiation in confluent conditions a–i. Stimulation with osteogenic d, g, adipogenic e, h, and chondrogenic f, i media caused a time-dependent
increase in alkaline phosphatase d, g, LipidTOX-Green/Foxo1 e, h and Aggrecan/Col2a1 f, i respectively. Addition of tazarotene to the induction
media causes a decrease in all differentiation markers a–i. Values are given as the mean ± SD, n = 3. *p <0.05, **p <0.005, ***p <0.001. DMSO
dimethyl sulfoxide
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and C646, respectively) to assess whether inhibiting such
modifications at the chromatin level would be sufficient
to block the effect of tazarotene on Scx nuclear trans-
location. For this experiment, cells were plated in the
presence of tazarotene while being co-treated with each
inhibitor for 4 DIV. As shown previously, Scx immuno-
fluorescence revealed strong nuclear translocation in
tazarotene-treated cells (Fig. 7a). Co-treatment with
C646 did not have an effect on Scx induction, whereas
BIX-01294 was able to suppress the SCX nuclear
localization. This indicates that histone methylation
plays a role Scx nuclear binding via RAR signaling
(Fig. 7b, c).
Discussion
Using a high-content imaging screen, we were able to
identify RAR agonists as potent inducers of Scx nuclear
binding in human TSCs. Stimulation of RARs on stem
cells from different origins have shown both pro-
differentiating and anti-differentiating activities [15–18].
However, the role of RAR in TSCs has not yet been
characterized. Although Scx appears to be necessary for
tendon development, it remains expressed in freshly
isolated TSCs from adult tendons. In our study we have
shown that maintaining Scx localization in the nucleus
using a RAR agonist does not necessarily induce teno-
genic differentiation but is rather associated with the
maintenance of the TSC phenotype, consistent with the
inhibition of differentiation towards multiple mesenchy-
mal lineages. Even though RAR agonists were identified
in our screen, it does not appear that their inhibitory ac-
tivity on differentiation is entirely mediated through Scx.
Knockdown experiments using small interfering mRNA
against Scx transcript did not revert the inhibition of
differentiation induced by tazarotene, suggesting that add-
itional transcription factors might be involved (Additional
file 7: Figure S6).
TSCs could be cultured in presence of tazarotene for
up to 20 passages with a similar population doubling
time compared with untreated cells. The maintenance of
stem cell marker expression levels remained similar for
up to 10 passages but slowly decreased afterwards, while
still remaining higher than untreated cells (Additional
file 5: Figure S4). It is possible that TSCs slowly become
irresponsive to tazarotene treatment following prolonged
exposure. At concentrations higher than 500 nM, we
Fig. 4 Stem cell marker maintenance following treatment with tazarotene a–d. Oct4 and Ssea-1 mRNA levels are higher in tazarotene-treated cells
compared with DMSO control a, b. Oct4 immunofluorescence staining after 4 days confirms higher nuclear levels in tazarotene-treated cells c, d.
Values are given as the mean ± SD, n = 3. *p <0.05, **p <0.005, ***p <0.001. DMSO dimethyl sulfoxide, Taz tazarotene
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could also observe a reduction in proliferation of about
50–75 %. Tazarotene is a selective RARβ and RARγ agon-
ist but it can also bind RARα at higher concentrations
[19]. Activation of RARα has been previously shown to in-
hibit cell proliferation in other cell types, which could ex-
plain the slow decrease in cell division we observed at
higher concentrations [20]. The anti-differentiation effect
of tazarotene appears to be partially conserved among dif-
ferent MSC types depending on their origin. We found
that tazarotene has similar activity on MSCs derived from
adipose tissue but has the opposite effect on MSCs iso-
lated from bone marrow by being pro-osteogenic (data
not shown). This suggests that RAR signaling might have
a different role in BM-MSCs.
Fig. 5 Tazarotene prevents spontaneous differentiation arising with extended culture time. TSCs were isolated from adult rat Achilles tendons
and plated at low density for colony formation before being trypsinized and grown with or without tazarotene (TZ). Messenger RNA was
collected at early (P1) and late passages (P4) for gene expression analysis a. In control conditions, several genes typical of TSC differentiation
towards multiple lineages were found upregulated in late passage cells (P1 vs P4), confirming spontaneous differentiation during in vitro cell
expansion b, d. Addition of tazarotene to the culture media was able to preserve TSC’s stemness as seen by cells from passage 4 having similar
expression levels to those of passage 1 c. Values are given as the mean ± SD, n = 3
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RARs have multiple functions at the nuclear level by
interacting with retinoid X receptors and other co-
repressor or activator proteins leading to epigenetic and
gene expression changes [21, 22]. Stem cell homeostasis
is usually maintained through these mechanisms that are
highly dynamic in regulating chromatin structure as well
as specific gene expression programs involved in self-
renewal and differentiation [23]. In general, stem cells
show a more decondensed chromatin which contributes
to an open or accessible state as compared with differen-
tiated cells [24]. The overall increased levels of histone
modifications, which are commonly transcriptionally ac-
tive regions, are enriched in stem cells while silenced re-
gions are strongly reduced compared with more
differentiated cells [25]. Our results suggest that RAR
agonists could preserve TSC stemness through epigen-
etic modifications, specifically involving histone methyla-
tion. Co-treatment with a histone methyltransferase
Fig. 6 Differentiation potential of tazarotene-expanded TSCs is conserved upon withdrawal. Tazarotene-expanded cells from passage 9 were
cultured with or without the compound for three further passages and induced to differentiate towards different mesenchymal lineages a.
Both conditions were equally able to differentiate into osteocytes, adipocytes, and chondrocytes as seen by upregulation of alkaline phosphatase,
LipidTOX, and aggrecan staining b, c, e, f, h, i. However, TSCs at the same passage cultured in a constant presence of tazarotene did not differentiate
d, g, j. DMSO dimethyl sulfoxide, Taz tazarotene
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inhibitor was sufficient to block tazarotene-induced Scx
nuclear localization, while an acetyltransferase inhibitor
did not have any effect.
It is possible that the binding elements and/or pro-
moter regions of Scx and other transcription factors crit-
ical for TSC identity are gradually repressed with
passages due to changes in chromatin structure. Inter-
estingly, hypoxia has been shown to preserve TSC stem-
ness in culture and further reduce differentiation in
culture conditions [26]. Another possible explanation
could be that mechanical loading in vitro is necessary
for maintaining TSC properties similar to what has been
shown for the maintenance Scx nuclear localization [9].
We can hypothesize that expansion in normoxia condi-
tions and/or in the absence of mechanical stimulation
might induce epigenetic changes responsible for the de-
crease in Scx nuclear binding and spontaneous differen-
tiation occurring during the expansion process. These
changes could be driven by an overall decrease in his-
tone methylation and could be potentially reversed using
RAR agonists. DNA methylation has also been shown to
prevent spontaneous differentiation of mesenchymal
progenitors in culture where removing methyl groups
using 5-azacytidine causes differentiation towards the
osteogenic and adipogenic cell fate [27]. The direct link
between RAR and Scx nuclear localization still remains
to be investigated. Further epigenetic analyses on TSCs
treated with RAR agonists should help elucidate this
process. Additionally, analyzing the methylation status of
the SCX gene as well as other key genes involved in self-
renewal and differentiation could reveal more details on
how RAR agonists affect the epigenetics of TSCs.
Conclusion
Cell-based therapies using adult stem cells harvested
from the target tissue represent a potential strategy to
address the unmet medical need for tendon regeneration
[28–30]. Recent advances in such an approach show
promising results but additional work is essential to
understand how best to expand and prepare these cells
for treatment and avoid premature differentiation during
the expansion process. These non-tendon committed
progenitors could potentially engraft following trans-
plantation to a site of tendon injury and interfere with
tendon healing and biomechanical properties by produ-
cing the wrong ECM in vivo. Tendon calcification and
cartilage-like differentiation has been observed in clinical
samples of tendinopathy, reinforcing the idea that
engrafting such non-tendon progenitors would be detri-
mental [31]. In this study, we demonstrated that TSCs,
like MSCs, undergo spontaneous differentiation in vitro
and that addition of a RAR agonist to the culture media
was able to prevent this process. In vivo studies compar-
ing TSCs expanded with or without a RAR agonist
should reinforce the use of molecules that preserve their
stem cell characteristics during the expansion phase.
Additional files
Additional file 1: is Table S1 presenting the quantitative PCR primer list.
(TIF 2735 kb)
Additional file 2: is Figure S1 showing Scx antibody specificity and TSC
identity. Transduced 293T cells using a lentivirus overexpressing Scx with
Zsgreen reporter show clear nuclear staining for Scx protein while control
lentiviral vector did not show any staining A, B. Only TSCs but not tenocytes
from the same tendon tissue were positive for Oct4, confirming that our
protocol for stem cell isolation was successful C, D. (TIF 4337 kb)
Additional file 3: is Figure S2 showing that tazarotene treatment
increases nuclear Scx translocation in human patellar TSCs. TSCs isolated
from human patellar tendon lose nuclear Scx localization with passages
A, C. Treatment with tazarotene at 100 nM is able to induce Scx nuclear
translocation similar to Achilles TSCs B, D, E. (TIF 1345 kb)
Additional file 4: is Figure S3 showing that tazarotene treatment
increases nuclear Scx translocation in rat Achilles TSCs. Western blot
showing enrichment in Scx protein in the nuclear extract A, B. (TIF 734 kb)
Fig. 7 Tazarotene induces Scx nuclear localization through histone modifications. Human TSCs from passage 4 were co-treated for 4 DIV with
histone methyltransferase and acetyltransferase inhibitors in the presence of tazarotene a–c. Addition of BIX-01294, a histone methyltransferase
inhibitor, was able to suppress Scx nuclear localization induced by tazarotene, while C646, a histone acetyltransferase inhibitor, did not have any
effect b, c. DMSO dimethyl sulfoxide, Scx scleraxis
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Additional file 5: is Figure S4 showing that tazarotene can maintain stem
cell marker expression in TSCs for up to 17 passages. mRNA levels of both
Oct4 and Ssea1 remain high in the presence of the drug for up to 17 passages
A. Withdrawal of the compound at passage 8 is followed by a rapid decrease
of both Oct4 and Ssea1 which is already visible at passage 10 B. (TIF 719 kb)
Additional file 6: is Figure S5 showing TSC expansion in the presence
of tazarotene does not affect the population doubling time. A growth
curve for up to passage 17 was performed and did not show statistical
difference with control DMSO-treated cells for concentrations between
20 and 500 nM A. Withdrawal of the compound at passage 8 is not
followed by a change in population doubling time B. (TIF 811 kb)
Additional file 7: is Figure S6 showing that Scx siRNA knockdown does
not suppress the inhibitory effect of tazarotene on osteogenic
differentiation. TSCs were transfected with siRNA against Scx or with a
siRNA control and were induced to differentiate towards the osteogenic
lineage and visualized by alkaline phosphatase staining A, B. The
inhibition of osteogenic differentiation in presence of tazarotene was not
blocked following Scx siRNA knockdown C, D. (TIF 3491 kb)
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